TWiV 1120: Clinical update with Dr. Daniel Griffin

This Week in Virology

In his weekly clinical update, Dr. Griffin reports the third case of influenza H5N1 infection in a human, this time with respiratory symptoms, an H5 avian influenza virus wastewater dashboard, FDA approves Moderna’s mRNA vaccine for respiratory syncytial virus, vaccine advisors to FDA recommend switching from the XBB.1.5 variant to JN.1 for fall COVID-19 vaccine formulations, weekly US COVID update, a controlled human exhaled breath aerosol experimental study on the relative efficacy of masks and respirators as source control for viral aerosol shedding from people infected with SARS-CoV-2, systematic review of early use of oral antiviral drugs and the risk of post COVID-19 syndrome, long-COVID autonomic syndrome in working age and work ability impairment, Centers for Disease Control and Prevention estimates that 5.3% of Americans currently have long COVID, and the National Academies of Sciences, Engineering, and Medicine presented a report with a number of conclusions about long-COVID diagnosis, symptoms, and impact on daily function.

Subscribe (free): Apple Podcasts, Google Podcasts, RSS, email

Become a patron of TWiV!

Links for this episode

• More cattle and dairy workers infected with highly pathogenic H5N1 in Michigan (CDC Newsroom)
• Not eye but respiratory human H5N1 in Michigan (CIDRAP)
• Emory and Stanford’sH5N1 dashboard (Emory and Stanford)
• FDA approval for MRESVIA(FDA)
• Moderna RSV vaccine for the elderly (CIDRAP)
• Moderna announces approval of MRESVIA (moderna)
• FDA VRBPAC meeting for fall COVID boosters (FDA)
• JN.1 variant for fall booster (CIDRAP)
• COVID-19 national trend (CDC)
• COVID-19 deaths (CDC)
• Masks and respirators for source control from viral aerosol shedding (Lancet)
• Spring vaccine advice (CIDRAP)
• Older adult spring booster available (CDC)
• Advisory committee for immunization practices slides (CDC)
• EUA for pemgarda (FDA)
• Where to get pemgarda (Pemgarda)
• CDC Quarantine guidelines (CDC)
• Early phase of SARs-CoV-2 infection (COVID.gov)
• NIH COVID-19 treatment guidelines (NIH)
• Infectious Disease Society guidelines for treatment and management (ID Society)
• Drug interaction checker (University of Liverpool)
• Molnupiravir safety and efficacy (JMV)
• Convalescent plasma recommendations for immunocompromised (IDSociety)
• Updated respiratory virus guidances (CDC)
• What to do when your healthcare provider is infected with SARS-CoV-2 (CDC)
• Managing healthcare staffing shortages (CDC)
• Steroids, dexamethasone at the right time (OFID)
• Anticoagulation guidelines (hematology.org)
• Early use of oral antiviral drugs and risk of long COVID (Journal of Infection)
• Early antiviral use associates with low risk of long COVID (CIDRAP)
• Long-COVID autonomic syndrome impairment (Scientific reports)
• Autonomic nervous assessment tool (hATTR)
• Do you know percentage of population with long COVID? (CDC National Center for Health Statistics)
• How many symptoms are there to long COVID? (CIDRAP)
• Long-term health effects of long COVID (National Academies of Sciences Engineering Medicine)
• Long COVID evidence based review TWiV shout out
• Contribute to our Floating Doctors fundraiser
• Letters read on TWiV 1120
• Dr. Griffin’s COVID treatment summary (pdf)
• Timestamps by Jolene. Thanks!

Intro music is by Ronald Jenkees

Send your questions for Dr. Griffin to [e-mail]